Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women

Back to Search
Print
Bookmark Trial

NCT00464789

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Menopause
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
35-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Postmenopausal women aged 35 to 70 years

- Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 and body weight greater than or equal to 50 kg

- Healthy as determined by the investigator on the basis of medical history, physical examination, breast and gynecologic examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any clinically important active condition of gynecologic, cardiovascular, hepatic,
renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic,
hematologic, neurologic, or psychiatric disease.


- History or current evidence of thrombophlebitis, thromboembolic disorders, or any
coagulopathies.


- History of any clinically important drug allergy to conjugated estrogens (CE) or
selective estrogen receptor modulators (SERMs).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

MenopauseStudy Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause NCT00195546
  1. Leuven,
  2. Zadar,
  3. Zagreb,
  4. Olomuc,
  5. Ostrava,
  6. Prerov,
  7. Kuopio,
  8. Kuopio,
  9. Oulu,
  10. Evry,
  11. Paris,
  12. Paris,
  13. Debrecen,
  14. Tatabanya,
  15. Del. Cuauhtemoc,
  16. Lomas Virrteyes,
  17. Den Bosch,
  18. Hengelo,
  19. Nijmegen,
  20. Katowice,
  21. Poznan,
  22. Warszawa,
  23. Wroclaw,
  24. Bucuresti,
  25. Bucuresti,
  26. Bucuresti,
  27. Bucuresti,
  28. Bloemfontein,
  29. Centurion,
  30. Parow,
  31. Madrid,
  32. Linköping,
  33. Stockholm,
  34. Uppsala,
  35. Donetsk,
  36. Kyiv,
  37. Kyiv,
  38. Fowey,
  39. Leicester,
  40. London,
  41. Plymouth,
Female
40 Years+
years
MULTIPLE SITES
MenopauseStudy Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation NCT00630435
Female
35 Years+
years
MULTIPLE SITES
MenopauseBioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women NCT00396799
Female
35 Years+
years
MULTIPLE SITES
MenopauseStudy Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women NCT00464789
Female
35 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women
Official Title  ICMJE An Open-Label, Single-Dose, Randomized, 3-Period, Crossover, Bioequivalence Study Between Bazedoxifene/Conjugated Estrogens (Premarin Current Process) And Bazedoxifene/Conjugated Estrogens (Premarin New Process) In Healthy Postmenopausal Women
Brief Summary Bazedoxifene/Conjugated Estrogens (BZA/CE) is an investigational drug that is being developed for treatment of menopause. The purpose of this trial is to compare a new manufacturing process for making BZA/CE to the current process by assessing the way it is absorbed into the blood.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Menopause
Intervention  ICMJE Drug: Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE Not Provided
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE May 2007
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Postmenopausal women aged 35 to 70 years
  • Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 and body weight greater than or equal to 50 kg
  • Healthy as determined by the investigator on the basis of medical history, physical examination, breast and gynecologic examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG).

Exclusion Criteria:

  • Any clinically important active condition of gynecologic, cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
  • History or current evidence of thrombophlebitis, thromboembolic disorders, or any coagulopathies.
  • History of any clinically important drug allergy to conjugated estrogens (CE) or selective estrogen receptor modulators (SERMs).
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 35 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00464789
Other Study ID Numbers  ICMJE 3115A1-1120
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP